Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-1
2024-516960-27-00Phase 2Completed
- Sponsor
- Morphic Therapeutic
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of LY4268989 in autoimmune colitis, sponsored by Morphic Therapeutic. Primary endpoint: Change from baseline to Week 12 in the Robarts Histopathology Index (RHI) Score. Started Nov 2024; status: completed.
02
Drugs
LY4268989
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-516960-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516960-27-00.